Phospho-ROS1 (Tyr2274) Antibody

• 产品编号：CST-3078S      品牌：CST       原厂货号：3078S
• 产品分类：抗体 > 一抗 > 磷酸化抗体
• 应用分类：

描述：

磷酸化Ros (Tyr2274) 抗体仅在Ros蛋白的Tyr 2274位点磷酸化时能检测到内源的Ros蛋白的表达。本抗体可能其它未知蛋白发生交叉反应。单克隆抗体通过用多肽免疫动物得到，该磷酸化多肽是根据人的Ros蛋白Tyr2274附近的氨基酸序列合成的。c-ros原癌基因编码一个酪氨酸激酶受体，该受体和胰岛素受体相似并表达在特殊的上皮细胞中(1)。在小鼠发育过程中， Ros 受体对附睾上皮层的分化十分重要 (2)。Ros的突变或过表达会导致癌变。此外，稳定转染含有Ros跨膜区和胞内区的嵌合受体能使NIH/3T3成纤维细胞转化(3)。 基因重组产生包含Ros和FIG（在恶性胶质瘤中融合）的融合蛋白会导致恶性胶质瘤的发生(4)。FIG-Ros的融合能异常激活肿瘤细胞中的SHP-2磷酸酶和PI3K/Akt/mTOR 通路(5)。 其它的Ros突变和NSCLC肿瘤细胞相关，这也提示Ros可能是肿瘤治疗的一个靶点 (6)。

1. Matsushime, H. et al. (1986) Mol Cell Biol 6, 3000-4.
2. Yeung, C.H. et al. (1999) Biol Reprod 61, 1062-9.
3. Charest, A. et al. (2003) Genes Chromosomes Cancer 37, 58-71.
4. Gu, T.L. et al. (2011) PLoS One 6, e15640.
5. Birch, A.H. et al. (2011) PLoS One 6, e28250.
6. Rimkunas, V.M. et al. (2012) Clin Cancer Res 18, 4449-57.
7. Rikova, K. et al. (2007) Cell 131, 1190-203.
8. Stumpfova, M. and Jänne, P.A. (2012) Clin Cancer Res 18, 4222-4.
9. Jun, H.J. et al. (2012) Cancer Res 72, 3764-74.

原厂资料：

Specificity / Sensitivity

Phospho-Ros (Tyr2274) Antibody detects endogenous levels of Ros only when phosphorylated at tyrosine 2274. This antibody may cross-react with other unknown proteins.

Source / Purification

Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Tyr2274 of human Ros.

Background

The c-ros proto-oncogene encodes a receptor tyrosine kinase similar to insulin receptor proteins and expressed in specific epithelial cells (1). During mouse development the Ros receptor plays an important role in the differentiation of epididymal epithelium (2). Overexpression or mutation of Ros may lead to oncogenic development. Furthermore, stable transfection with a chimeric receptor containing the Ros transmembrane and cytoplasmic domains leads to transformation of NIH/3T3 fibroblasts (3). A genetic rearrangement that produces a fusion protein containing Ros and FIG (fused in glioblastoma) results in glioblastoma formation (4). The FIG-Ros fusion abnormally activates the SHP-2 phosphatase and PI3K/Akt/mTOR pathways in tumor cells (5). Additional Ros mutations are associated with NSCLC cancer cells indicating that Ros may be a candidate for tumor targeted therapy (6).

1. Matsushime, H. et al. (1986) Mol Cell Biol 6, 3000-4.
2. Yeung, C.H. et al. (1999) Biol Reprod 61, 1062-9.
3. Charest, A. et al. (2003) Genes Chromosomes Cancer 37, 58-71.
4. Gu, T.L. et al. (2011) PLoS One 6, e15640.
5. Birch, A.H. et al. (2011) PLoS One 6, e28250.
6. Rimkunas, V.M. et al. (2012) Clin Cancer Res 18, 4449-57.
7. Rikova, K. et al. (2007) Cell 131, 1190-203.
8. Stumpfova, M. and Jänne, P.A. (2012) Clin Cancer Res 18, 4222-4.
9. Jun, H.J. et al. (2012) Cancer Res 72, 3764-74.

注意事项：

Storage: Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody.